Breast Cancer

EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.

Camizestrant is the first cancer therapy guided by a ctDNA resistance mutation detected before imaging shows disease progression.

NICE’s family history–based referral criteria identified just 4.4% of women under 50 who developed breast cancer within 10 years.

The phase 2 AZTEC trial found that single- and multifraction SABR, followed by atezolizumab, had similar safety profiles and limited efficacy in advanced TNBC.

Compared with conventional imaging alone, patient-reported outcomes integrated with machine learning may provide an earlier indication of breast cancer recurrence, disease progression, and survival.

The approval of the drug combination is supported by findings from the phase 3 VIKTORIA-1 clinical trial.

The tool can estimate recurrence risk across multiple subtypes, including those for which no guideline-recommended genomic prognostic tests currently exist.

Priority review NDA puts oral SERD giredestrant on PDUFA track for ER-positive, HER2-negative breast cancer, after reduced recurrence risk in lidERA trial.

Supported by improved progression-free survival outcomes in the phase 3 ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, sacituzumab govitecan-hziy received FDA approval as both a monotherapy and combination therapy with pembrolizumab.

The FDA approved palbociclib-based maintenance therapy for HR-positive, HER2-positive advanced breast cancer following a significant progression-free survival benefit in PATINA.

Results from the SERENA-6 trial show that an early switch to the oral selective estrogen receptor degrader camizestrant combined with a CDK4/6 inhibitor improves progression-free survival 2, delays chemotherapy, and preserves quality of life.

Data presented at ASCO 2026 show giredestrant plus palbociclib extends PFS in ER+/HER2– metastatic breast cancer; FDA approval is on the horizon.

ASCENT-04 updated data show sacituzumab govitecan plus pembrolizumab extends benefit past progression in PD-L1+ metastatic TNBC.

Emerging evidence links GLP-1 receptor agonists to improved breast cancer outcomes and the growing importance of metabolic health in survivorship care.

Proteomic liquid biopsy technology may improve early breast cancer detection, guide targeted therapy selection, and support longitudinal treatment monitoring in oncology care.

Researchers discuss how GLP-1 receptor agonists may be associated with improved survival outcomes in breast cancer and what clinicians should consider as use of these therapies continues to grow.

The approval is supported by data from the phase 3 TROPION-Breast02 trial.

The FDA approved 2 new indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer, expanding its use in both neoadjuvant and adjuvant settings.

A new JAMA study links GLP-1s like Wegovy, Ozempic, Zepbound, and Mounjaro to better breast cancer survival, lower recurrence, and weight loss benefits.

Phase 3 findings from the VIKTORIA-1 trial demonstrated clinically meaningful progression-free survival improvements with gedatolisib-based regimens in patients with PIK3CA-mutant HR+/HER2– advanced breast cancer.

Study data show that extended endocrine therapy after 5 years reduces late recurrence in premenopausal breast cancer, with benefits varying by tumor subtype.

New NCCN updates make sacituzumab govitecan a preferred first-line option in metastatic TNBC. Jordan Hill, PharmD, BCOP, explains the impact.

AACR data show tumor molecular profiling finds actionable PIK3CA in breast and colorectal cancer, while ctDNA adds real-time monitoring in oncology.